Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 60-week, multicentre, randomised, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 28 weeks of treatment compared to Ustekinumab and to assess long term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis

Next Previous
Trial Profile

A 60-week, multicentre, randomised, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 28 weeks of treatment compared to Ustekinumab and to assess long term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation

Most Recent Events

  • 30 Mar 2016 Status changed from active, no longer recruiting to completed.
  • 22 Aug 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top